Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046524 | 1.00 | NPFFR1 (0.39) | NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL242270 | 0.94 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL10046298 | 0.85 | NPFFR1 (0.33) | NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL19446136 | 0.83 | NPFFR1 (0.32) | NPFFR1NPFFR2L3MBTL1MAPTHPGD | |
| SCHEMBL22005285 | 0.82 | GAA (0.33) | ALDH1A1KMT2AHPGDGAAMEN1 | |
| SCHEMBL22005196 | 0.82 | RECQL (0.33) | ALDH1A1HPGD | |
| SCHEMBL15500314 | 0.82 | NPFFR1 (0.32) | NPFFR1NPFFR2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL3122796 | 0.82 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL2734924 | 0.82 | APLNR (0.36) | L3MBTL1ALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL21862213 | 0.82 | CTSS (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131526-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-7375083-B2 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-7223735-B2 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-20090131526-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | NPFFR1 3506/4885NPFFR2 3557/4885L3MBTL1 4082/4885 |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | NPFFR1 1716/4885NPFFR2 1857/4885L3MBTL1 258/4885 |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPFFR1 1255/4885NPFFR2 1520/4885L3MBTL1 836/4885 |
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | NPFFR1 3897/4885NPFFR2 3815/4885L3MBTL1 1186/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | NPFFR1 2923/4885NPFFR2 4109/4885L3MBTL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.